Antibody and T cell recognition of the light chain of botulinum neurotoxin A in two high-responder mouse strains

Immunobiology

Volumn 217, Issue 1, 2012, Pages 1-7

  Atassi, M Zouhair ^a   Oshima, Minako ^a   Dolimbek, Behzod Z ^a   Aoki, K Roger ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b ALLERGAN INC   (United States)

Author keywords

Antibody recognition regions; Antigenic structure; Botulinum neurotoxin A; Genetic restriction; Light chain; Synthetic peptides; T cell recognition regions

Indexed keywords

BOTULINUM TOXIN A; STAPHYLOCOCCUS PROTEIN A;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY DETECTION; ARTICLE; BAGG ALBINO MOUSE; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; EPITOPE MAPPING; FEMALE; GENETIC REGULATION; IN VITRO STUDY; ISOTOPE LABELING; LETHAL DOSE; MOLECULAR RECOGNITION; MOUSE; NONHUMAN; PEPTIDE ANALYSIS; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN STRUCTURE; SWISS JAMES LAMBERT MOUSE; T LYMPHOCYTE;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, BACTERIAL; BOTULINUM TOXINS, TYPE A; CELLS, CULTURED; CLOSTRIDIUM BOTULINUM; EPITOPE MAPPING; EPITOPES, B-LYMPHOCYTE; EPITOPES, T-LYMPHOCYTE; FEMALE; IMMUNE SERA; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; MICE; MICE, INBRED C57BL; MOLECULAR SEQUENCE DATA; NEUROTOXINS; PEPTIDE FRAGMENTS; RADIOIMMUNOASSAY; SPECIES SPECIFICITY; TOXOIDS;

EID: 82155195846     PISSN: 01712985     EISSN: 18783279     Source Type: Journal    
DOI: 10.1016/j.imbio.2011.09.001     Document Type: Article

References (60)

1. Adekar S.P., Takahashi T., Jones R.M., Al-Saleem F.H., Ancharski D.M., Root M.J., Kapadnis B.P., Simpson L.L., Dessain S.K. Neutralization of botulinum neurotoxin by a human monoclonal antibody specific for the catalytic light chain. PLoS One 2008, 3(8):e3023.
2. Aoki K.R., Smith L.A., Atassi M.Z. Mode of action of botulinum neurotoxins: current vaccination strategies and molecular immune recognition. Crit. Rev. Immunol. 2010, 30(2):167-187.
3. Atassi M.Z., Dolimbek B.Z., Manshouri T. Antibody and T-cell recognition of α-bungarotoxin and its synthetic loop peptides. Mol. Immunol. 1995, 32(12):919-929.
4. Atassi M.Z. Basic immunological aspects of botulinum toxin therapy. Mov. Disord. 2004, 19(Suppl. 8):S68-S84.
5. Atassi M.Z., Dolimbek G.S., Deitiker P.R., Aoki K.R., Dolimbek B.Z. Submolecular recognition profiles in two mouse strains of non-protective and protective antibodies against botulinum neurotoxin A. Mol. Immunol. 2005, 42(12):1509-1520.
6. Atassi M.Z., Dolimbek B.Z., Jankovic J., Steward L.E., Aoki K.R. Regions of botulinum neurotoxin A light chain recognized by human anti-toxin antibodies from cervical dystonia patients immunoresistant to toxin treatment. The antigenic structure of the active toxin recognized by human antibodies. Immunobiology 2011, 216(7):782-792.
7. Atassi M.Z., Oshima M. Structure, activity, and immune (T and B cell) recognition of botulinum neurotoxins. Crit. Rev. Immunol. 1999, 19(3):219-260.
8. Atassi M.Z. Antigenic structures of proteins. Their determination has revealed important aspects of immune recognition and generated strategies for synthetic mimicking of protein binding sites. Eur. J. Biochem. 1984, 145(1):1-20.
9. Atassi M.Z., Bixler G.S. Comparison of the submolecular recognition of proteins by T and B cells. Vaccines: New Concepts and Developments 1988, 58-70. Longman Scientific and Technical, Essex. H. Kohler, P.T. LoVerde (Eds.).
10. Atassi M.Z., Dolimbek B.Z. Mapping of the antibody-binding profile on botulinum neurotoxin A HN-domain (residues 449-859) with anti-toxin antibodies from four host species. Antigenic profile of the entire H-chain of botulinum neurotoxin A. Protein J. 2004, 23(1):39-52.
11. Atassi M.Z., Dolimbek B.Z., Hayakari M., Middlebrook J.L., Whitney B., Oshima M. Mapping of the antibody-binding regions on botulinum neurotoxin H-chain domain 855-1296 with anti-toxin antibodies from three host species. J. Protein Chem. 1996, 15(7):691-700.
12. Atassi M.Z., Yoshioka M., Bean M., Bixler G.S. Non-specific peptide size effects in the recognition by site-specific T-cell clones: demonstration with a T site of myoglobin. Biochem. J. 1987, 246(2):307-312.
13. Bixler G.S., Atassi M.Z. Molecular localization of the full profile of the continuous regions recognized by myoglobin primed T-cells using synthetic overlapping peptides encompassing the entire molecule. Immunol. Commun. 1983, 12(6):593-603.
14. Bixler G.S., Atassi M.Z. T-cell recognition of myoglobin. Localization of the sites stimulating T-cell proliferative responses by synthetic overlapping peptides encompassing the entire molecule. J. Immunogenet. 1984, 11(5-6):339-353.
15. Bixler G.S., Bean M., Atassi M.Z. Site recognition by protein-primed T cells show a non-specific peptide size requirement beyond the essential residues of the site: demonstration by defining an immunodominant T site in myoglobin. Biochem. J. 1986, 240(1):139-146.
16. Chicz R.M., Urban R.G., Gorga J.C., Vignali D.A., Lane W.S., Strominger J.L. Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles. J. Exp. Med. 1993, 178(1):27-47.
17. Childers M.K. Clinical application of botulinum neurotoxin in the treatment of myofascial pain syndrome. Botulinum Toxin. Therapeutic Clinical Practice and Science 2008, 283-294. Saunders Elsevier. J. Jankovic, A. Albanese, M.Z. Atassi, J.O. Dolly, M. Hallett, N.H. Mayer (Eds.).
18. Comella C.L., Jankovic J., Shannon K.M., Tsui J., Swenson M., Leurgans S., Fan W., Dystonia Study Group Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia. Neurology 2005, 65(9):1423-1429.
19. David C.S., Atassi M.Z. Genetic control and intersite influences on the immune response to sperm whale myoglobin. Adv. Exp. Med. Biol. 1982, 150:97-125.
20. Dolimbek B.Z., Atassi M.Z. α-Bungarotoxin peptides afford a synthetic vaccine against toxin poisoning. J. Protein Chem. 1994, 13(5):490-493.
21. Dolimbek B.Z., Atassi M.Z. Protection against α-bungarotoxin poisoning by immunization with synthetic toxin peptides. Mol. Immunol. 1996, 33(7-8):681-689.
22. Dolimbek B.Z., Steward L.E., Aoki K.R., Atassi M.Z. Regions of recognition by blocking antibodies on the light chain of botulinum neurotoxin A. Antigenic structure of the entire toxin. Immunobiology 2011, 216(6):698-706.
23. Dolimbek B.Z., Aoki K.R., Atassi M.Z. Reduction of antibody response against botulinum neurotoxin A by synthetic monomethoxypolyethylene glycol-peptide conjugates. Immunol. Lett. 2011, 137(1-2):46-52.
24. Dolimbek G.S., Dolimbek B.Z., Aoki K.R., Atassi M.Z. Mapping of the antibody and T cell recognition profiles of the HN domain (residues 449-859) of the heavy chain of botulinum neurotoxin A in two high-responder mouse strains. Immunol. Invest. 2005, 34(2):119-142.
25. Dolimbek B.Z., Aoki K.R., Steward L.E., Jankovic J., Atassi M.Z. Mapping of the regions on the heavy chain of botulinum neurotoxin A (BoNT/A) recognized by antibodies of cervical dystonia patients with immunoresistance to BoNT/A. Mol. Immunol. 2007, 44(5):1029-1041.
26. Dong J., Thompson A.A., Fan Y., Lou J., Conrad F., Ho M., Pires-Alves M., Wilson B.A., Stevens R.C., Marks J.D. A single-domain llama antibody potently inhibits the enzymatic activity of botulinum neurotoxin by binding to the noncatalytic alpha-exosite binding region. J. Mol. Biol. 2010, 397(4):1106-1118.
27. Dressler D., Bigalke H. Antibody-induced failure of botulinum toxin type B therapy in de novo patients. Eur. Neurol. 2004, 52(3):132-135.
28. Dressler D., Bigalke H., Benecke R. Botulinum toxin type B in antibody-induced botulinum toxin type A therapy failure. J. Neurol. 2003, 250(8):967-969.
29. Fu F.N., Lomneth R.B., Cai S., Singh B.R. Role of zinc in the structure and toxic activity of botulinum neurotoxin. Biochemistry 1998, 37(15):5267-5278.
30. Gammon G., Klotz J., Ando D., Sercarz E.E. The T cell repertoire to a multideterminant antigen. Clonal heterogeneity of the T cell response, variation between syngeneic individuals, and in vitro selection of T cell specificities. J. Immunol. 1990, 144(5):1571-1577.
31. Glaser D.A. Botulinum neurotoxin for dermatologic and cosmetic disorders. Botulinum Toxin. Therapeutic Clinical Practice and Science 2008, 324-338. Saunders Elsevier. J. Jankovic, A. Albanese, M.Z. Atassi, J.O. Dolly, M. Hallett, N.H. Mayer (Eds.).
32. Göschel H., Wohlfarth K., Frevert J., Dengler R., Bigalke H. Botulinum A toxin therapy: neutralizing and nonneutralizing Abs-therapeutic consequences. Exp. Neurol. 1997, 147(1):96-102.
33. Greene P., Fahn S., Diamond B. Development of resistance to botulinum toxin type A in patients with torticollis. Mov. Disord. 1994, 9(2):213-217.
34. Hamajima S., Atassi M.Z. B-cell activation in vitro by helper T cells specific to a protein region that is recognized both by T cells and by antibodies. Immunol. Invest. 1998, 27(3):121-134.
35. Hunter W.M., Greenwood F.C. Preparation of iodine-131 labelled human growth hormone of high specific activity. Nature (Lond.) 1962, 194(4827):495-496.
36. Jankovic J. Botulinum toxin: clinical implications of antigenicity and immunoresistance. Scientific and Therapeutic aspects of Botulinum Toxin 2002, 409-415. Lippincott Williams and Wilkins, Philadelphia. M. Brin, J. Hallett, J. Jankovic (Eds.).
37. Jankovic J. Botulinum toxin in clinical practice. J. Neurol. Neurosurg. Psychiatr. 2004, 75:951-957.
38. Jankovic J. Treatment of cervical dystonia with botulinum toxin. Mov. Disord. 2004, 19(Suppl. 8):S109-S115.
39. Jankovic J., Hunter C., Dolimbek B.Z., Dolimbek G.S., Adler C.H., Brashear A., Comella C.L., Gordon M., Riley D.E., Sethi K., Singer C., Stacy M., Tarsy D., Atassi M.Z. Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia. Neurology 2006, 67(12):2233-2235.
40. Kazim A.L., Atassi M.Z. Haemoglobin binding with haptoglobin. Unequivocal demonstration that the β-chains of human haemoglobin bind to haptoglobin. Biochem. J. 1980, 185(1):285-287.
41. Kazim A.L., Atassi M.Z. Structurally inherent antigenic sites: localization of the antigenic sites of the α-chain of human haemoglobin in three host species by a comprehensive synthetic approach. Biochem. J. 1982, 203(1):201-208.
42. Kenney C., Jankovic J. Botulinum neurotoxin treatment of cranial cervical dystonia. Botulinum Toxin. Therapeutic Clinical Practice and Science 2008, 92-101. Saunders Elsevier. J. Jankovic, A. Albanese, M.Z. Atassi, J.O. Dolly, M. Hallett, N.H. Mayer (Eds.).
43. Maruta T., Dolimbek B.Z., Aoki K.R., Steward L.E., Atassi M.Z. Mapping of the synaptosome-binding regions on the heavy chain of botulinum neurotoxin A by synthetic overlapping peptides encompassing the entire chain. Protein J. 2004, 23(8):539-552.
44. Meloen R.H., Casal J.I., Dalsgaard K., Langeveld J.P.M. Synthetic peptide vaccines: success at last. Vaccine 1995, 13(10):885-886.
45. Montecucco C., Schiavo G. Structure and function of tetanus and botulinum neurotoxins. Q. Rev. Biohys. 1995, 28(4):423-472.
46. Naumann M., Toyka K.V., Mansouri Taleghani B., Ahmadpour J., Reiners K., Bigalke H. Depletion of neutralising antibodies resensitises a secondary nonresponder to botulinum A neurotoxin. J. Neurol. Neurosurg. Psychiatry 1998, 65(6):924-927.
47. Okuda K., Twining S.S., David C.S., Atassi M.Z. Genetic control of immune response to sperm whale myoglobin in mice. II. T lymphocyte proliferative response to the synthetic antigenic sites. J. Immunol. 1979, 123(1):182-188.
48. Okuda K.P., Christadoss R., Twining S.S., Atassi M.Z., David C.S. Genetic control of immune response to sperm whale myoglobin in mice. I. T-lymphocyte proliferative response under H-2 linked Ir gene control. J. Immunol. 1978, 121(3):866-868.
49. Oshima M., Hayakari M., Middlebrook J.L., Atassi M.Z. Immune recognition of botulinum neurotoxin type A: regions recognized by T cells and antibodies against the protective H(C) fragment (residues 855-1296) of the toxin. Mol. Immunol. 1997, 34(14):1031-1040.
50. Oshima M., Middlebrook J.L., Atassi M.Z. Antibodies and T cells against synthetic peptides of the C-terminal domain (Hc) of botulinum neurotoxin type A and their cross-reaction with Hc. Immunol. Lett. 1998, 60(1):7-12.
51. Rosenberg J.S., Atassi M.Z. Intersite helper function of T cells specific for a protein epitope that is not recognized by antibodies. Immunol. Invest. 1997, 26(4):473-489.
52. Rosenberg J.S., Middlebrook J.L., Atassi M.Z. Localization of the regions on the C-terminal domain of the heavy chain of botulinum A recognized by T lymphocytes and by antibodies after immunization of mice with pentavalent toxoid. Immunol. Invest. 1997, 26(4):491-504.
53. Rosenberg J.S., Oshima M., Atassi M.Z. B-cell activation in vitro by helper T cells specific to region alpha 146-162 of Torpedo californica nicotinic acetylcholine receptor. J. Immunol. 1996 Oct 1, 157(7):3192-3199.
54. Schiavo G., Poulain B., Rossetto O., Benfenati F., Tauc L., Montecucco C. Tetanus toxin is a zinc protein and its inhibition of neurotransmitter release and protease activity depend on zinc. EMBO J. 1992, 11(10):3577-3583.
55. Schiavo G., Rossetto O., Santucci A., DasGupta B.R., Montecucco C. Botulinum neurotoxins are zinc proteins. J. Biol. Chem. 1992, 267(33):23479-23483.
56. Silberstein S.D. Botulinum neurotoxin in headache management. Botulinum Toxin. Therapeutic Clinical Practice and Science 2008, 214-222. Saunders Elsevier. J. Jankovic, A. Albanese, M.Z. Atassi, J.O. Dolly, M. Hallett, N.H. Mayer (Eds.).
57. Simeckova-Rosenberg J., Yun Z., Wyde P.R., Atassi M.Z. Protection of mice against lethal viral infection by synthetic peptides corresponding to B- and T-cell recognition sites of influenza A hemagglutinin. Vaccine 1995, 13(10):927-932.
58. Simpson L.L. Peripheral actions of the botulinum toxins. Botulinum Neurotoxin and Tetanus Toxin 1989, 153-178. Academic Press, New York. L.L. Simpson (Ed.).
59. Sloop R.R., Cole B.A., Escutin R.O. Human response to botulinum toxin injection: type B compared with type A. Neurology 1997, 49(1):189-194.
60. Twining S.S., David C.S., Atassi M.Z. Genetic control of the immune response to myoglobin. IV. Mouse antibodies in outbred and congenic strains against sperm whale myoglobin recognize the same antigenic sites that are recognized by antibodies raised in other species. Mol. Immunol. 1981, 18(5):447-450.